CONSULTING AND MARKETING
LICENSE AGREEMENT
THIS CONSULTING AND MARKETING LICENSE AGREEMENT, (the "Agreement") is between
▇▇▇▇ ▇▇▇▇▇▇▇ (the "Consultant") and DNAPrint genomics, Inc. (the "Company"). The
Consultant and the Company are also referred to in this Agreement as the
"Parties".
WHEREAS, the Company intends to develop a market for the Company's Retinome DNA
testing products, along with other products currently under development by the
Company (the "Products and Services").
WHEREAS, the Consultant has contacts in the medical products industry who may be
willing to assist the Company in developing commercial applications and
distribution for its products; and
WHEREAS, the Company desires to utilize the services of the Consultant to
promote and develop such a market for the Company's Products and Services; and
WHEREAS, in connection with the services to be provided by the Consultant
pursuant to this Agreement, the Company desires to engage the Consultant to
assist the Company through identification, introduction, and other forms of
assistance in developing commercial markets for the Retinome DNA testing
products and other products of the Company, grant the Consultant a non-exclusive
license for the limited use of the Company's tradename, trademark, or logo, or
any other tradename, trademark or logo of the Company, to engage the Consultant
to assist the Company through identification, introduction, and other forms of
assistance in developing commercial markets for the Retinome DNA testing
products and other products of the Company, and to as may be agreed upon by the
Parties (the "Licensed Trademarks"); and
NOW THEREFORE, in consideration of the premises and mutual covenants set forth
in this Agreement, the Parties hereby agree as follows:
1. Scope of Services. The Company hereby retains the Consultant to promote and
develop a market for the Products and Services. The Consultant agrees to
use his best efforts during the term of this Agreement to market and
promote the Products and Services.
2. Term. This Agreement shall become effective as of the date set forth on the
signature page of this Agreement, and shall continue for a period of one
(1) year (the "Term"). Notwithstanding the foregoing, the Company or the
Consultant shall be entitled to terminate this Agreement for "cause" upon
thirty (30) days written notice, which written notice shall be effective
upon mailing by first class mail accompanied by facsimile transmission to
the Consultant at the address and facsimile number last provided by the
Consultant to the Company. "Cause" shall be determined solely as to the
violation of any rule or regulation of any regulatory agency, and other
neglect, act or omission detrimental to the conduct of the Company or the
Consultant's business, material breach of this Agreement or any
unauthorized disclosure of any of the secrets or confidential information
of the Company, and dishonesty related to independent contractor status.
1
3. Grant of Non-exclusive License. Subject to the terms of this Agreement, the
Company hereby engages the Consultant to assist the Company through
identification, introduction and other forms of assistance in developing
commercial markets for the DNA testing Retinome products and other products
of the Company and grants to the Consultant, and the Consultant hereby
accepts, the non-exclusive license to use the Licensed Trademarks on the
Consultant's racing cars, and on the Consultants racing equipment and
clothing, which shall be operated by the Consultant in professional racing
car competitions at the sole discretion of the Consultant. The Company
shall supply all camera ready artwork either on disk or via email.
a. During the Term of this Agreement the Consultant shall not negotiate or
enter into any license, sub-license agreement of sub-contract or similar
agreement with any third parties in respect of the Company's Products and
Services, or other right or interest granted by the Company to the
Consultant to such third parties without the Company's prior written
consent.
b. No license or right is granted by the Company to the Consultant, either
expressly or by implication, under any licenses or rights owned or
controlled by the Company, except as expressly set forth in this Agreement.
c. The license granted pursuant to this Agreement shall expire simultaneously
with the Term of this Agreement, and shall be revocable at will by the
Company upon written notice to the Consultant, and the Consultant shall
immediately refrain from the use of any rights granted by the Company to
the Consultant with respect to this license upon receipt of such written
notice.
4. Compensation; Grant of Stock Option. In consideration for the services to
be provided by the Consultant to the Company under the terms of this
Agreement, the Company agrees to grant to the Consultant upon the execution
of this Agreement a non-qualified stock option (the "Option") to purchase
up to the number of shares (the "Shares") of the Company's common stock
(the "Common Stock") as set forth below which shall fully vest immediately
upon execution of this Agreement, at an exercise price as set forth below:
Number of Shares or Total Dollar Amount: $1,000,000.00 or (20,000,000 Shares)
whichever produces greater benefit to the Company.
Exercise Price per Share or Percentage per Share (in U.S. $): Previous fifteen
(15) day low.
The terms of the Option shall otherwise be set forth in a Non-Qualified Stock
Option Agreement between the Company and the Consultant, substantially in the
form attached as Exhibit A to this Agreement. The Company agrees to register the
Shares upon signing of this Agreement for resale under the Securities Act of
1933, as amended, pursuant to a registration statement filed with the Securities
and Exchange Commission on Form S-8 (or, if Form S-8 is not then available, such
2
other form of registration statement available), pursuant to the terms of such
registration set forth in the Non-Qualified Stock Option Agreement.
5. Confidentiality. The Consultant covenants that all information concerning
the Company, including proprietary information, which it obtains as a
result of the services rendered pursuant to this Agreement shall be kept
confidential and shall not be used by the Consultant except for the direct
benefit of the Company nor shall the confidential information be disclosed
by the Consultant to any third party without the prior written approval of
the Company, provided, however, that the Consultant shall not be obligated
to treat as confidential, or return to the Company copies of any
confidential information that (i) was publicly known at the time of
disclosure to Consultant, (ii) becomes publicly known or available
thereafter other than by any means in violation of this Agreement or any
other duty owned to the Company by the Consultant, or (iii) is lawfully
disclosed to the Consultant by a third party.
6. Independent Contractor. The Consultant and the Company hereby acknowledge
that the Consultant is an independent contractor. The Consultant agrees not
to hold himself out as, nor shall he take any action from which others
might reasonably infer that the Consultant is a partner or agent of, or a
joint venturer with the Company. In addition, the Consultant shall take no
action which, to the knowledge of the Consultant, binds, or purports to
bind, the Company to any contract or agreement.
7. Miscellaneous.
a. Entire Agreement. This Agreement contains the entire agreement between the
Parties, and may not be waived, amended, modified or supplemented except by
agreement in writing signed by the Party against whom enforcement of any
waiver, amendment, modification or supplement is sought. Waiver of or
failure to exercise any rights provided by this Agreement in any respect
shall not be deemed a waiver of any further or future rights.
b. Governing Law. This Agreement shall be construed under the internal laws of
the State of California, and the Parties agree that the exclusive
jurisdiction for any litigation or arbitration arising from this Agreement
shall be in Los Angeles, California or New York City, New York.
c. Successors and Assigns. This Agreement shall be binding upon the Parties,
their successors and assigns, provided, however, that the Consultant shall
not permit any other person or entity to assume these obligations hereunder
without the prior written approval of the Company which approval shall not
be unreasonably withheld and written notice of the Company's position shall
be given within ten (10) days after approval has been requested.
d. Indemnification. The Company shall indemnify the Consultant for all losses
or damages sustained (including reasonable attorney fees and disbursements)
as incurred by the Consultant arising from the Consultant performing
services under this Agreement.
3
e. Counterparts. This Agreement may be executed in two (2) or more
counterparts, each of which shall be deemed an original, but which when
taken together shall constitute one (1) agreement.
f. Severability. If one (1) or more provisions of this Agreement are held to
be unenforceable under applicable law, such provision(s) shall be excluded
from this Agreement and the balance of this Agreement shall be interpreted
as if such provision were excluded and shall be enforceable in accordance
with its terms.
IN WITNESS WHEREOF, the Parties hereto have executed or caused this Agreement to
be executed as of the date set forth below.
CONSULTANT: Date:
▇▇▇▇ ▇▇▇▇▇▇▇
Address for Notices:
▇▇ ▇. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇, #▇▇▇
▇▇▇▇, ▇▇ ▇▇▇▇▇
COMPANY: Date:
DNAPrint genomics, Inc.
By:
Name
Title
4
EXHIBIT A
FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT
THIS NON-QUALIFIED STOCK OPTION AGREEMENT (the "Agreement") is between ▇▇▇▇
▇▇▇▇▇▇▇ (the "Grantee") and the other party named on the signature page to this
Agreement (the "Company"). Each of the Grantee and the Company are also referred
to in this Agreement as the "Parties".
WHEREAS, the Board of Directors of the Company (the "Board of Directors") has
authorized the grant to the Grantee, for services to be rendered by the Grantee
as a Consultant to the Company pursuant to the Terms of a Consulting and
Marketing License Agreement (the "Consulting Agreement") between the Company and
the Grantee, of a non-qualified stock option (the "Option") to purchase the
number of shares of the Company's common stock (the "Common Stock") specified in
paragraph 1 of this Agreement, at the price specified in paragraph 1 of this
Agreement.
NOW THEREFORE, in consideration of the premises and mutual covenants set forth
in this Agreement, the Parties hereby agree as follows:
1. Number of Shares; Exercise Price. Pursuant to action taken by the Board of
Directors, the Company hereby grants to the Grantee, in consideration of
consulting services to be performed for the benefit of the Company pursuant
to the Consulting Agreement, an option (the "Option") to purchase the
number of common shares (the "Option Shares") of Common Stock set forth
below, at the exercise price set forth below:
Total Dollar Amount: $1,000,000.00 or (20,000,000 Shares) whichever is greater
to the Company.
Exercise Price per Share or Percentage per Share (in U.S. $): Previous fifteen
(15) day low.
2. Term. The Option and this Agreement shall expire one (1) year from the date
of this Agreement.
3. Shares Subject to Exercise. The Option shall be immediately exercisable and
shall remain exercisable for the entire Term specified in Paragraph 2 of
this Agreement.
4. Method and Time of Exercise. The Option may be exercised in whole or from
time to time in part by written notice delivered to the Company stating the
number of Option Shares with respect to which the Option is then being
exercised, together with a check and/or a wire transfer made payable to the
Company in the amount equal to the Exercise Price multiplied by the number
of Option Shares then being issued pursuant to the written notice of
exercise, plus the amount of applicable federal, state and local
withholding taxes, provided, however, that such taxes may be satisfied by
the withholding of Option Shares then issuable upon the exercise of the
Option pursuant to Paragraph 5 of this Agreement. Not less than one hundred
(100) Option Shares may be purchased upon exercise of the Option at any one
5
time unless the number of Option Shares for which exercise of the Option is
being made is all of the Option Shares then issuable upon exercise of the
Option. Only whole shares shall be issued upon exercise of the Option.
5. Tax Withholding. As a condition to exercise the Option, the Company may
require the Grantee to pay to the Company all applicable federal, state and
local taxes which the Company is required to withhold with respect to the
exercise of the Option. Or the Grantee is liable for filing and paying all
of his own taxes.
6. Exercise Following Termination of Consulting Agreement. The Option shall
not terminate as a result of the termination of Grantee's services as a
Consultant to the Company pursuant to the Consulting Agreement.
7. Transferability. The Option and this Agreement may not be assigned or
transferred except by will or by the laws of descent and distribution, and
with the consent of the Company.
8. Grantee Not a Shareholder. The Grantee shall have no rights as a
shareholder with respect to the Option Shares issued from time to time upon
exercise of the Option until the earlier of: (i) the date of issuance of a
stock certificate or stock certificates to the Grantee applicable to the
Option Shares then issuable to the Grantee upon exercise of the Option and
(ii) the date on which the Grantee or his nominee is recorded as owner of
such Option Shares on the Company's stock ledger by the Company's registrar
and transfer agent, which may be the Company. Except as set forth in
Paragraph 13 of this Agreement, no adjustment will be made for dividends or
other rights for which the record date is prior to the earlier of the
events described in clauses (1) and (2) of this Paragraph.
9. Restrictions on Transfer. The Grantee represents and agrees that, upon the
Grantee's exercise of the Option in whole or in part, unless there is in
effect at that time under the Securities Act of 1933 a registration
statement relating to the Option Shares, the Grantee will acquire the
Option Shares for the purpose of investment and not with a view to their
resale or further distribution, and that upon such exercise hereof, the
Grantee will furnish to the Company a written statement to such effect,
satisfactory to the Company in form and substance.
10. Shares Qualified for Listing. The Company represents that its Common Stock
is qualified for trading or quotation on a nationally recognized securities
exchange or stock quotation system, including, without the NASDAQ Bulletin
Board, and for trading with the California Department of Corporations or
such other applicable jurisdictions.
11. Registration Rights. On or before the day of this Agreement, the Company
shall, at the Company's expense, file with the Securities and Exchange
Commission (the "SEC"), a registration statement (the "Registration
Statement") on Form S-8 or other comparable form, or if such form is not
then available, such other form of registration statement then available,
in such form as to comply with applicable federal and state laws for the
purpose of registering or qualifying the Option Shares for public resale by
the Grantee, and prepare and file with the appropriate state securities
regulatory authorities the documents reasonably necessary to register or
6
qualify the Option Shares, subject to the ability of the Company to
register or qualify the Option Shares under applicable state law.
12. Notices. All notices to the Company shall be addressed to the Company at
the principal office of the Company at the address and facsimile number set
forth on the signature page of this Agreement, and all notices to the
Grantee shall be addressed to the Grantee at the address and facsimile
number of the Grantee set forth on the signature page of this Agreement or,
if different, the last address and facsimile number on file with the
Company, or to such other address and facsimile number as either may
designate to the other in writing. A notice shall be deemed to be duly
given if and when enclosed in a properly addressed sealed envelope
deposited, postage prepaid and followed by facsimile to the addressee. In
lieu of giving notice by mail as aforesaid, written notices under this
Agreement may be given by personal delivery to the Grantee or to the
Company (as the case may be) by a nationally recognized overnight courier
or delivery service.
13. Adjustments. If there is any change in the capitalization of the Company
after the date of this Agreement affecting in any manner the number of kind
of outstanding shares of Common Stock of the Company, whether by stock
dividend, stock split, reclassification or recapitalization of such stock,
or because the Company has merged or consolidated with one or more other
corporations (and provided the Option does not thereby terminate pursuant
to Paragraph 14 of this Agreement), then the number and kind of shares then
subject to the Option and the exercise price to be paid for the Option
Shares shall be appropriately adjusted by the Board of Directors; provided,
however, that in no event shall any such adjustment result in the Company
being required to sell or issue any fractional shares. Any such adjustment
shall be made without change in the aggregate exercise price applicable to
the unexercised portion of the Option, but with an appropriate adjustment
to the exercise price of each Option Share or other unit of security then
covered by the Option and this Agreement.
14. Cessation of Corporate Existence. Notwithstanding any other provision of
this Agreement, in the event of the reorganization, merger or consolidation
of the Company with one or more corporations as a result of which the
Company is not the surviving corporation, or the sale of substantially all
the assets of the Company or of more than fifty percent (50%) of the then
outstanding stock of the Company to another corporation or other entity in
a single transaction, the Option granted hereunder shall terminate,
provided, however, that not later than five (5) days before the effective
date of such merger or consolidation or sale of assets in which the Company
is not the surviving corporation, the surviving corporation may, but shall
not be so obligated to, tender to the Grantee an option to purchase a
number of shares of capital stock of the surviving corporation equal to the
number of Option Shares then issuable upon exercise of the Option, and such
new option or options for shares of the surviving corporation shall contain
such terms, conditions and provisions as shall be required substantially to
preserve the rights and benefits of the Option and this Agreement.
15. Miscellaneous.
a. Entire Agreement. This Agreement and the Consulting Agreement contain the
entire agreement between the Parties, and may not be waived, amended,
7
modified or supplemented except by agreement in writing signed by the Party
against whom enforcement of any waiver, amendment, modification or
supplement is sought. Waiver of or failure to exercise any rights provided
by this Agreement and the Consulting Agreement in any respect shall not be
deemed a waiver of any further or future rights.
b. Governing Law. This Agreement shall be construed under the internal laws of
the State of California, and the Parties agree that the exclusive
jurisdiction for any litigation or arbitration arising from this Agreement
shall be in Los Angeles, California or New York City, New York.
c. Counterparts. This Agreement may be executed in two (2) or more
counterparts, each of which shall be deemed an original, but which when
taken together shall constitute one (1) agreement.
d. Severability. If one (1) or more provisions of this Agreement are held to
be unenforceable under applicable law, such provision(s) shall be excluded
from this Agreement and the balance of this Agreement shall be interpreted
as if such provision were excluded and shall be enforceable in accordance
with its terms.
IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the
date set forth below:
OPTIONEE: Date:
▇▇▇▇ ▇▇▇▇▇▇▇
Address for Notices:
▇▇ ▇. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇, #▇▇▇
▇▇▇▇, ▇▇ ▇▇▇▇▇
COMPANY: Date:
By:
Name
Title
8
EXHIBIT B
OPTION EXERCISE SCHEDULE
$250,000 immediately upon registration
$250,000 on November 15, 2001
$250,000 on December 15, 2001
$250,000 on January 15, 2002
Company agrees to grant an additional $1,000,000 to optionee upon having the
Company's Authorized Shares increased.
IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the
date set forth below:
OPTIONEE: Date:
▇▇▇▇ ▇▇▇▇▇▇▇
Address for Notices:
▇▇ ▇. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇, #▇▇▇
▇▇▇▇, ▇▇ ▇▇▇▇▇
COMPANY: Date:
DNAPrint genomics, Inc.
By:
Name
Title
9
DNAP Open High Low Close Change Volume
10/30/01 0.09 0.10 0.07 0.07 -0.02 7,621,100
10/29/01 0.12 0.12 0.08 0.09 -0.02 14,484,200
10/26/01 0.11 0.12 0.11 0.12 +0.01 5,291,900
10/25/01 0.11 0.11 0.10 0.11 +0.00 4,482,800
10/24/01 0.10 0.11 0.09 0.10 +0.01 6,417,500
10/23/01 0.13 0.13 0.09 0.10 -0.01 8,823,400
10/22/01 0.09 0.11 0.08 0.11 +0.03 9,971,500
10/19/01 0.07 0.08 0.07 0.08 +0.01 6,403,700
10/18/01 0.07 0.07 0.06 0.06 +0.00 1,851,900
10/17/01 0.06 0.07 0.06 0.06 +0.01 3,552,700
10/16/01 0.06 0.06 0.05 0.06 +0.00 1,727,100
10/15/01 0.05 0.05 0.05 0.05 +0.00 1,616,200
10/12/01 0.04 0.05 0.04 0.05 +0.00 4,447,600
10/11/01 0.05 0.05 0.04 0.05 +0.00 2,056,200
10/10/01 0.05 0.05 0.04 0.05 -0.00 1,594,000
10
DNAPL13.1
